JNJ-7706621 (Standard)

Overview

JNJ-7706621 (Standard) is the analytical standard of JNJ-7706621 ( HY-10329 ). This product is intended for research and analytical applications. JNJ-7706621 is a potent aurora kinase inhibitor , and also inhibits CDK1 and CDK2 , with IC 50 s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1 , CDK2 , aurora-A and aurora-B, respectively.

Application

Products | Products > Signaling Pathways > Others | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > Aurora Kinase | Products > Signaling Pathways > CDK | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-10329R
• CAS No.: 443797-96-4
• Molecular Formula: C15H12F2N6O3S
• Molecular Weight: 394.36
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source